Figure 3.

Systemic investigation of lenti-HA in orthotopic C57BL/6 HCC mice. Lenti-HA (3x10⁷ or 5x10⁶ copies) or lenti-AFP (3x10⁷ copies) was subcutaneously administered into day-7 established orthotopic HCC mice for 3 weeks at weekly interval. (A) Schematic diagram for the dosing regimen of lentiviral vaccines in day-7 orthotopic C57BL/6 HCC mice. (B) Representative tumor images for treated orthotopic HCC mice. (C) Analysis of tumor volume and weight from orthotopic HCC mice treated with lenti-HA or lenti-AFP (n=5, *P<0.05; **P<0.01). Flow cytometric analysis of CD4⁺ or CD8⁺ T lymphocytes (D) or IFN-γ-expressing CD8⁺ T lymphocytes (E) or CD4⁺CD25⁺ Tregs (F) in blood from orthotopic C57BL/6 HCC mice treated with lenti-AFP or lenti-HA 3 days after last injection (n=5, **P<0.01). Measurement of IL-10 and TGF-β (G) or IFN-γ and IL-2 (H) in blood from orthotopic HCC mice treated with lenti-HA or lenti-AFP (n=5, **P<0.01). Two-tailed t test was used for statistical analysis and all experiments were repeated twice (two repeated experiments yielded similar results and thus one representative result was shown).